Sheded, M., Hassan, A., Hassanein, E. (2019). Assessment of Liver Morbidity in Breast Cancer Patients Receiving Chemotherapy in Suez Canal University Hospitals. Afro-Egyptian Journal of Infectious and Endemic Diseases, 9(1), 3-11. doi: 10.21608/aeji.2019.28431
Mahmoud M Sheded; Adel A Hassan; Ehab M Hassanein. "Assessment of Liver Morbidity in Breast Cancer Patients Receiving Chemotherapy in Suez Canal University Hospitals". Afro-Egyptian Journal of Infectious and Endemic Diseases, 9, 1, 2019, 3-11. doi: 10.21608/aeji.2019.28431
Sheded, M., Hassan, A., Hassanein, E. (2019). 'Assessment of Liver Morbidity in Breast Cancer Patients Receiving Chemotherapy in Suez Canal University Hospitals', Afro-Egyptian Journal of Infectious and Endemic Diseases, 9(1), pp. 3-11. doi: 10.21608/aeji.2019.28431
Sheded, M., Hassan, A., Hassanein, E. Assessment of Liver Morbidity in Breast Cancer Patients Receiving Chemotherapy in Suez Canal University Hospitals. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2019; 9(1): 3-11. doi: 10.21608/aeji.2019.28431
Assessment of Liver Morbidity in Breast Cancer Patients Receiving Chemotherapy in Suez Canal University Hospitals
1Infectious and Endemic Hepatology and Gastroenterology Department, Faculty of Medicine, Suez University, Egypt
2Infectious Diseases Department, Faculty of Medicine, Suez Canal University, Egypt
3Oncology and Nuclear medicine Department, Faculty of Medicine, Suez Canal University, Egypt
Abstract
Background and study aim: In Egypt, breast cancer, representing 18.9% of total cancer cases and 35.1% of cancer in women. Potential interactions between the liver and chemotherapy fall into direct chemotherapy-induced hepatotoxicity and Potentiation of preexisting liver disease, especially viral hepatitis.The aim of the study is to assess liver morbidity in breast cancer patients before and 3 months after chemotherapy to assess reactivation of viral hepatitis. Subjects and Methods: This study is prospective study; It included 88 female patients who received chemotherapy for breast cancer. Results: Before chemotherapy 9 patients (10.2%) & 11 patients (12.5%) had elevated ALT & AST respectively which increased after chemotherapy to 32 patients (36.4%) & 29 patients (33%) respectively. Two patients (2.3%) had low serum albumin which increased after chemotherapy to 18 patients (20.5%). None of the patients had elevated S. bilirubin, ascites or jaundice, while after chemotherapy 10 patients (11.4%) had elevated S. bilirubin, 5 patients (5.6%) and 6 patients (6.8%) developed ascites and jaundice respectively. Regarding Child score: None of the patients had Child B/C score before treatment, while after chemotherapy 6 patients (6.8%) developed Child B/C score. Regarding viral hepatitis, 2 of ten patients (20%) who were HBcIgG positive, HBsAg negative with undetectable HBV DNA by PCR developed evidence of HBV reactivation in form of positive PCR for both & reversion of HBsAg for one patient. Conclusion: Chemotherapy for breast cancer carries high risk for hepatotoxicity and reactivation of viral hepatitis.
View on SCiNiTO
Top